Nuvalent (NUVL) Stock Forecast & Price Target

Compare

152 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NUVL Analyst Ratings

Strong Buy

16 Buy

0 Hold

0 Sell

Based on 16 analysts giving stock ratings to

Nuvalent

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NUVL Stock 12 Month Forecast

Average Price Target

$140.86

▲(35.70% Upside)

Based on 16 Wall Street analysts offering 12 month price targets for Nuvalent in the last 3 months. The average price target is $140.86 with a high forecast of $158.00 and a low forecast of $125.00. The average price target represents a 35.70% change from the last price of $103.80.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"67":"$67","90":"$90","113":"$113","136":"$136","159":"$159"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":158,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$158.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":140.86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$140.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":125,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$125.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[67,90,113,136,159],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,106.42,110.3876923076923,114.35538461538462,118.32307692307693,122.29076923076923,126.25846153846155,130.22615384615386,134.19384615384615,138.16153846153847,142.1292307692308,146.09692307692308,150.0646153846154,154.0323076923077,{"y":158,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,106.42,109.06923076923077,111.71846153846154,114.36769230769231,117.01692307692308,119.66615384615385,122.31538461538462,124.9646153846154,127.61384615384617,130.26307692307694,132.9123076923077,135.56153846153848,138.21076923076924,{"y":140.86,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,106.42,107.84923076923077,109.27846153846154,110.70769230769231,112.13692307692308,113.56615384615385,114.99538461538461,116.42461538461538,117.85384615384615,119.28307692307692,120.71230769230769,122.14153846153846,123.57076923076923,{"y":125,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":94.27,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.28,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.81,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":74.98,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.23,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.18,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.76,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.9,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.58,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.32,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.42,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$158.00

Average Price Target$140.86

Lowest Price Target$125.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Anupam Rama

J.P. Morgan

$147→$145

Buy

39.69%

Upside

Reiterated

12/18/25

Nuvalent price target lowered to $145 from $147 at JPMorganNuvalent price target lowered to $145 from $147 at JPMorgan

Etzer Darout

Barclays

$152

Buy

46.44%

Upside

Reiterated

12/17/25

Analysts Are Bullish on Top Healthcare Stocks: Nuvalent (NUVL), Novan (NOVN)

Gregory Renza

Truist Financial

Buy

―

Reiterated

12/17/25

Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Novan (NOVN)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$125

Buy

20.42%

Upside

Reiterated

12/08/25

Wedbush Sticks to Its Buy Rating for Nuvalent (NUVL)

Kelsey Goodwin

Piper Sandler

$128

Buy

23.31%

Upside

Reiterated

11/20/25

Piper Sandler Remains a Buy on Nuvalent (NUVL)

Swayampakula Ramakanth

H.C. Wainwright

$130→$155

Buy

49.33%

Upside

Reiterated

11/18/25

Nuvalent's Promising Future: Buy Rating Backed by ALKOVE-1 Study Success and Strategic Growth Plans

Richard Law CFA

Goldman Sachs

$120→$135

Buy

30.06%

Upside

Reiterated

11/18/25

Analysts' Top Healthcare Picks: Theravance Biopharma (TBPH), Nuvalent (NUVL)

Colleen M. Kusy

Robert W. Baird

$112→$158

Buy

52.22%

Upside

Reiterated

11/18/25

Nuvalent price target raised to $158 from $112 at BairdNuvalent price target raised to $158 from $112 at Baird

Charles Zhu

LifeSci Capital

$120→$142

Buy

36.80%

Upside

Reiterated

11/17/25

Nuvalent's Neladalkib: Promising ALK+ NSCLC Treatment with Strong Phase 2 Data and De-risked Approval Path

Andrew Berens

Leerink Partners

$140→$149

Buy

43.55%

Upside

Reiterated

11/17/25

Nuvalent price target raised to $149 from $140 at LeerinkNuvalent price target raised to $149 from $140 at Leerink

Marc Frahm

TD Cowen

Buy

―

Reiterated

11/17/25

Nuvalent (NUVL) Receives a Buy from TD Cowen

Bradley Canino

Guggenheim

$122→$155

Buy

49.33%

Upside

Reiterated

11/17/25

Guggenheim Keeps Their Buy Rating on Nuvalent (NUVL)

Laura Prendergast

Stifel Nicolaus

$115→$135

Buy

30.06%

Upside

Reiterated

11/17/25

Nuvalent price target raised to $135 from $115 at StifelNuvalent price target raised to $135 from $115 at Stifel

John Newman

Canaccord Genuity

$126

Buy

21.39%

Upside

Reiterated

11/17/25

Nuvalent's Neladalkib Shows Superior Efficacy and Safety in Clinical Trials

David Dai

UBS

$114→$132

Buy

27.17%

Upside

Reiterated

10/31/25

Nuvalent price target raised to $132 from $114 at UBSNuvalent price target raised to $132 from $114 at UBS

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Anupam Rama

J.P. Morgan

$147→$145

Buy

39.69%

Upside

Reiterated

12/18/25

Nuvalent price target lowered to $145 from $147 at JPMorganNuvalent price target lowered to $145 from $147 at JPMorgan

Etzer Darout

Barclays

$152

Buy

46.44%

Upside

Reiterated

12/17/25

Analysts Are Bullish on Top Healthcare Stocks: Nuvalent (NUVL), Novan (NOVN)

Gregory Renza

Truist Financial

Buy

―

Reiterated

12/17/25

Analysts Are Bullish on These Healthcare Stocks: Nuvalent (NUVL), Novan (NOVN)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$125

Buy

20.42%

Upside

Reiterated

12/08/25

Wedbush Sticks to Its Buy Rating for Nuvalent (NUVL)

Kelsey Goodwin

Piper Sandler

$128

Buy

23.31%

Upside

Reiterated

11/20/25

Piper Sandler Remains a Buy on Nuvalent (NUVL)

Swayampakula Ramakanth

H.C. Wainwright

$130→$155

Buy

49.33%

Upside

Reiterated

11/18/25

Nuvalent's Promising Future: Buy Rating Backed by ALKOVE-1 Study Success and Strategic Growth Plans

Richard Law CFA

Goldman Sachs

$120→$135

Buy

30.06%

Upside

Reiterated

11/18/25

Analysts' Top Healthcare Picks: Theravance Biopharma (TBPH), Nuvalent (NUVL)

Colleen M. Kusy

Robert W. Baird

$112→$158

Buy

52.22%

Upside

Reiterated

11/18/25

Nuvalent price target raised to $158 from $112 at BairdNuvalent price target raised to $158 from $112 at Baird

Charles Zhu

LifeSci Capital

$120→$142

Buy

36.80%

Upside

Reiterated

11/17/25

Nuvalent's Neladalkib: Promising ALK+ NSCLC Treatment with Strong Phase 2 Data and De-risked Approval Path

Andrew Berens

Leerink Partners

$140→$149

Buy

43.55%

Upside

Reiterated

11/17/25

Nuvalent price target raised to $149 from $140 at LeerinkNuvalent price target raised to $149 from $140 at Leerink

Marc Frahm

TD Cowen

Buy

―

Reiterated

11/17/25

Nuvalent (NUVL) Receives a Buy from TD Cowen

Bradley Canino

Guggenheim

$122→$155

Buy

49.33%

Upside

Reiterated

11/17/25

Guggenheim Keeps Their Buy Rating on Nuvalent (NUVL)

Laura Prendergast

Stifel Nicolaus

$115→$135

Buy

30.06%

Upside

Reiterated

11/17/25

Nuvalent price target raised to $135 from $115 at StifelNuvalent price target raised to $135 from $115 at Stifel

John Newman

Canaccord Genuity

$126

Buy

21.39%

Upside

Reiterated

11/17/25

Nuvalent's Neladalkib Shows Superior Efficacy and Safety in Clinical Trials

David Dai

UBS

$114→$132

Buy

27.17%

Upside

Reiterated

10/31/25

Nuvalent price target raised to $132 from $114 at UBSNuvalent price target raised to $132 from $114 at UBS

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Nuvalent

1 Month

xxx

Success Rate

6/8 ratings generated profit

Average Return

+4.79%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 75.00% of your transactions generating a profit, with an average return of +4.79% per trade.

3 Months

xxx

Success Rate

10/14 ratings generated profit

Average Return

+8.37%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +8.37% per trade.

1 Year

Swayampakula RamakanthH.C. Wainwright

Success Rate

7/8 ratings generated profit

Average Return

+30.00%

reiterated a buy rating last month

Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +30.00% per trade.

2 Years

xxx

Success Rate

9/9 ratings generated profit

Average Return

+57.61%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +57.61% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NUVL Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NUVL has received 31 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NUVL average Analyst price target in the past 3 months is 140.86.

Each month's total comprises the sum of three months' worth of ratings.

NUVL Financial Forecast

NUVL Earnings Forecast

Next quarter’s earnings estimate for NUVL is -$1.48 with a range of -$1.71 to -$1.34. The previous quarter’s EPS was -$1.70. NUVL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year NUVL has Performed in-line its overall industry.

No data currently available

NUVL Sales Forecast

Next quarter’s sales forecast for NUVL is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. NUVL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year NUVL has Performed in-line its overall industry.

NUVL Stock Forecast FAQ

What is NUVL’s average 12-month price target, according to analysts?

Based on analyst ratings, Nuvalent’s 12-month average price target is 140.86.

What is NUVL’s upside potential, based on the analysts’ average price target?

Nuvalent has 35.70% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NUVL a Buy, Sell or Hold?

Nuvalent has a consensus rating of Strong Buy which is based on 16 buy ratings, 0 hold ratings and 0 sell ratings.

What is Nuvalent’s price target?

The average price target for Nuvalent is 140.86. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $158.00 ,the lowest forecast is $125.00. The average price target represents 35.70% Increase from the current price of $103.8.

What do analysts say about Nuvalent?

Nuvalent’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.

How can I buy shares of NUVL?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Nuvalent (NUVL) Stock Forecast & Price Target

NUVL Analyst Ratings

NUVL Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Nuvalent

NUVL Analyst Recommendation Trends

NUVL Financial Forecast

NUVL Earnings Forecast

NUVL Sales Forecast

NUVL Stock Forecast FAQ

Detailed List of Analyst Forecasts